Open Label Study of Long Term Evaluation Against LDL-C Trial

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1324 participants.

Also called NCT01439880

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 1,324 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01439880
  • EudraCT 2011-001915-29
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Belgium, Canada, Czechia, Denmark, Finland, Germany, Hong Kong SAR China, Hungary, Japan, Netherlands, Norway, Singapore, South Africa, Spain, Sweden, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01439880. Randomized; no masking; primary purpose treatment. Start 2011-10-07 (actual); primary completion 2018-06-20 (actual). Results posted on 2019-07-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Open Label Study of Long Term Evaluation Against LDL-C Trial
Acronym
OSLER
Condition
Hypercholesterolemia
Intervention (Biological)
Evolocumab
Intervention (Other)
Standard of care
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct01439880
Content hash
e3b1d4c8d04394e3d8a9de6cce316cd07fbc35642d936b98e10c10eba3fbed50